These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26747766)

  • 1. Choroidal Response to Anti-VEGF Therapy in Subgroups Classified by Preexisting Ophthalmic or Systemic Condition.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8364. PubMed ID: 26747766
    [No Abstract]   [Full Text] [Related]  

  • 2. Tailoring Myopic CNV Treatment Based on Preexisting Ophthalmic Condition.
    Zhou TE; Bhosle VK; Chemtob S
    Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8362-3. PubMed ID: 26747765
    [No Abstract]   [Full Text] [Related]  

  • 3. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook.
    Munk MR; Rückert R; Zinkernagel M; Ebneter A; Wolf S
    Expert Opin Biol Ther; 2016; 16(4):477-87. PubMed ID: 26666589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research progress of treatment strategies for choroidal neovascularization secondary to pathological myopia].
    Shi XH; Wei WB
    Zhonghua Yan Ke Za Zhi; 2019 Oct; 55(10):791-795. PubMed ID: 31607068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new treatment algorithm for the management of myopic choroidal neovascularization using intravitreal ranibizumab.
    Iacono P; Parodi MB; Papayannis A; La Spina C; Varano M; Bandello F
    Acta Ophthalmol; 2015 Sep; 93(6):e519-20. PubMed ID: 25828793
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.
    Pece A; Milani P; Monteleone C; Trombetta CJ; De Crecchio G; Fasolino G; Matranga D; Cillino S; Vadalà M
    Graefes Arch Clin Exp Ophthalmol; 2015 Nov; 253(11):1867-72. PubMed ID: 25500986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of recurrence time intervals after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization.
    Takao-Okuma H; Terao R; Nagahara M; Azuma K; Inoue T; Uemura Y; Obata R
    Can J Ophthalmol; 2021 Apr; 56(2):137-138. PubMed ID: 32919998
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab.
    Smith AG; Kaiser PK
    Dev Ophthalmol; 2016; 55():246-51. PubMed ID: 26501149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent management of myopic choroidal neovascularization and rhegmatogenous retinal detachment with intravitreal antivascular endothelial growth factor during primary retinal detachment repair.
    Saurabh K; Roy R; Thomas NR; Chowdhury M
    Indian J Ophthalmol; 2018 Mar; 66(3):472-474. PubMed ID: 29480274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia.
    Hashemi S; Faramarzi MA; Ghasemi Falavarjani K; Abdollahi M
    Expert Opin Biol Ther; 2014 Dec; 14(12):1837-48. PubMed ID: 25283631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.
    Zhang Y; Han Q; Ru Y; Bo Q; Wei RH
    Drug Des Devel Ther; 2015; 9():3413-21. PubMed ID: 26170626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacotherapy of Myopic Choroidal Neovascularization.
    Isildak H; Schwartz SG; Flynn HW
    Curr Pharm Des; 2018; 24(41):4853-4859. PubMed ID: 30674251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.
    Miyake M; Yamashiro K; Akagi-Kurashige Y; Kumagai K; Nakata I; Nakanishi H; Oishi A; Tsujikawa A; Yamada R; Matsuda F; Yoshimura N
    Ophthalmology; 2014 Jan; 121(1):225-233. PubMed ID: 23953100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence?
    Lai TY
    Retina; 2012 Sep; 32(8):1443-5. PubMed ID: 22922844
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anti-VEGF therapy for juxtafoveolar choroidal neovessels in people with high myopia: about a case].
    Moustaine MO; Dellali F; Husseini AE; Hirsch AL
    Pan Afr Med J; 2017; 26():98. PubMed ID: 28491229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents.
    Adatia FA; Luong M; Munro M; Tufail A
    Surv Ophthalmol; 2015; 60(3):204-15. PubMed ID: 25890624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NAIVE IDIOPATHIC CHOROIDAL NEOVASCULARIZATION: A Comparative Study.
    Sudhalkar A; Yogi R; Chhablani J
    Retina; 2015 Jul; 35(7):1368-74. PubMed ID: 25830696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor for myopic choroidal neovascularization.
    Ng DS; Kwok AK; Chan CW
    Clin Exp Ophthalmol; 2012; 40(1):e98-e110. PubMed ID: 21902785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage 1 Type 3 Neovascularization With Choroidal Dilation Unresponsive to Anti-VEGF Treatment.
    Vujosevic S; Martini F; Midena E
    Ophthalmic Surg Lasers Imaging Retina; 2016 Oct; 47(10):956-959. PubMed ID: 27759863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.